Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Navidea Biopharmaceuticals Inc (NYSE MKT LLC:NAVB)

0.7366
Delayed Data
As of Dec 06
 +0.0015 / +0.20%
Today’s Change
0.26
Today|||52-Week Range
1.51
-44.62%
Year-to-Date
Company News for November 28, 2016
Nov 28 / Zacks.com - Paid Partner Content
Cardinal Health to Acquire Lymphoseek Rights for $80 Million
Nov 25 / Zacks.com - Paid Partner Content
Navidea Inks Deal to to Sell Lymphoseek to Cardinal Health
Nov 25 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close0.74
Today’s open0.75
Day’s range0.71 - 0.75
Volume470,209
Average volume (3 months)1,788,462
Market cap$114.5M
Dividend yield--
Data as of 12/06/2016

Growth & Valuation

Earnings growth (last year)+25.00%
Earnings growth (this year)+55.56%
Earnings growth (next 5 years)--
Revenue growth (last year)+111.15%
P/E ratioNM
Price/Sales15.18
Price/Book--

Competitors

 Today’s
change
Today’s
% change
FBIOFortress Biotech Inc+0.10+4.29%
FLKSFlex Pharma Inc+0.03+0.48%
ECYTEndocyte Inc+0.10+3.76%
MSLIMerus Labs Internati...+0.01+1.43%
Data as of 12/06/2016

Financials

Next reporting dateMarch 9, 2017
EPS forecast (this quarter)-$0.01
Annual revenue (last year)$13.2M
Annual profit (last year)-$27.6M
Net profit margin-213.76%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Mike M. Goldberg
Chief Operating &
Financial Officer
Jed Andrew Latkin
Corporate headquarters
Dublin, Ohio

Forecasts


Search for Jobs